tbuckley/cabot-search huggingface dataset:
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Authors: Yoshitsugu Mitani, Sue-Hwa Lin, Kristen B. Pytynia, Renata Ferrarotto, Adel K. El-Naggar
Journal: Clinical Cancer Research (2019)

Abstract Purpose: To determine the expression of glucocorticoid receptor (GR) and androgen receptor (AR) in salivary duct carcinoma (SDC) and to analyze the role of these proteins in the development and management of this disease entity. Experimental Design: We performed a phenotypic assessment of GR and AR localization and expression, and determined their association with clinicopathologic factors in 67 primary SDCs. In vitro functional and response analysis of SDC cell lines was also performed. Results: Of the 67 primary tumors, 12 (18%) overexpressed GR protein, 30 (45%) had constitutive expression, and 25 (37%) had complete loss of expression. Reciprocal GR and AR expression was found in 32 (48%) tumors, concurrent constitutive GR and AR expression in 23 (34%), and simultaneous loss of both receptors and high GR with AR expressions were found in 12 (18%). GR overexpression was significantly associated with worse clinical outcomes. In vitro ligand-independent AR activation was observed in both male- and female-derived cell lines. GR antagonist treatment resulted in decreased cell proliferation and survival in GR-overexpressing cells, irrespective of AR status. Reciprocal GR- and AR-knockdown experiments revealed an independent interaction. Conclusions: Our study, for the first time, demonstrates differential GR and AR expressions, autonomous GR and AR activation, and ligand-independent AR expression and activation in SDC cells. The findings provide critical information on the roles of GR and AR steroid receptors in SDC tumorigenesis and development of biomarkers to guide targeted steroid receptor therapy trials in patients with these tumors.
The role of GDF15 (growth/differentiation factor 15) during prostate carcinogenesis.
Authors: Sudha Sadasivan, Yalei Chen, Nilesh S Gupta, Kanika Taneja, S A Maresh, A Gonzalez, Xiaoxia Han, Kuan-Han Hank Wu, Dhananjay A Chitale, A Rundle, D Tang, Benjamin A Rybicki
Journal: Cancer Research (2018)
A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Authors: Aaron T. Gerds, Alessandro M. Vannucchi, Francesco Passamonti, Marina Kremyanskaya, Jason R. Gotlib, Jeanne M. Palmer, Kelly McCaul, Vincent Ribrag, Adam J. Mead, Claire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, Giovanni Barosi, Robert Peter Gale, Abderrahmane Laadem, Joseph Pariseau, Torsten Gerike, Jennie Zhang, Peter G. Linde, Joseph G. Reynolds, Srdan Verstovsek
Journal: Blood (2019)
A Process for Assessing Products for Infection Prevention in Health Care Settings: A Framework From the Healthcare Infection Control Practices Advisory Committee of the Centers for Disease Control and Prevention
Authors: Vineet Chopra, Lynn Janssen, Kristina Bryant, Loretta Fauerbach, Thomas R. Talbot, Hillary M. Babcock
Journal: Annals of Internal Medicine (2019)

Infection control is a complex task that spans people, products, and practices in diverse settings. For years, the Healthcare Infection Control Practices Advisory Committee (HICPAC) has provided advice and guidance to the Centers for Disease Control and Prevention (CDC) on how best to prevent infections. These recommendations have focused largely on health care delivery practices and occasionally on general categories of products. With an influx of novel infection control products and growing use of these products by frontline clinicians, an efficient process for developing transparent, rigorous product recommendations that includes myriad data sources was necessary. To address this gap, the CDC asked HICPAC to develop a process that would help inform committees considering product-related recommendations. This article describes the process to develop this approach and provides an outline of how the tool may be used when products with infection control claims are recommended in guidelines or recommendations for infection prevention.
There is little evidence that the Industrial Revolution was caused by a preference shift
Authors: David Hirshleifer, Siew Hong Teoh
Journal: Behavioral and Brain Sciences (2019)

Abstract The idea, based on Life History Theory, that the Industrial Revolution was a positive feedback process wherein prosperity induced prosperity-promoting preference shifts is just an intriguing speculation. The evidence does not distinguish this explanation from simple alternatives. For example, increased prosperity may have freed up time for individuals to engage in innovative activity and increased the benefits from doing so.
Characterizing the interplay between gene nucleotide composition bias and splicing
Authors: Sébastien Lemaire, Nicolas Fontrodona, Fabien Aubé, Jean-Baptiste Claude, Hélène Polvèche, Laurent Modolo, Cyril F. Bourgeois, Franck Mortreux, Didier Auboeuf
Journal: Genome biology (2019)

Abstract Background Nucleotide composition bias plays an important role in the 1D and 3D organization of the human genome. Here, we investigate the potential interplay between nucleotide composition bias and the regulation of exon recognition during splicing. Results By analyzing dozens of RNA-seq datasets, we identify two groups of splicing factors that activate either about 3200 GC-rich exons or about 4000 AT-rich exons. We show that splicing factor–dependent GC-rich exons have predicted RNA secondary structures at 5′ ss and are dependent on U1 snRNP–associated proteins. In contrast, splicing factor–dependent AT-rich exons have a large number of decoy branch points, SF1- or U2AF2-binding sites and are dependent on U2 snRNP–associated proteins. Nucleotide composition bias also influences local chromatin organization, with consequences for exon recognition during splicing. Interestingly, the GC content of exons correlates with that of their hosting genes, isochores, and topologically associated domains. Conclusions We propose that regional nucleotide composition bias over several dozens of kilobase pairs leaves a local footprint at the exon level and induces constraints during splicing that can be alleviated by local chromatin organization at the DNA level and recruitment of specific splicing factors at the RNA level. Therefore, nucleotide composition bias establishes a direct link between genome organization and local regulatory processes, like alternative splicing.
Increased CD8+CD28− circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis
Authors: Charles Cassius, Mylene Branchtein, Maxime Battistella, Reyhan Amode, Clémence Lepelletier, Marie Jachiet, Adèle de Masson, Laure Frumholtz, François Chasset, Jean-Benoit Monfort, Claude Bachmeyer, Djaouida Bengoufa, Florence Cordoliani, Martine Bagot, Armand Bensussan, Hélène Le Buanec, Jean-David Bouaziz
Journal: Journal of the American Academy of Dermatology (2019)
Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Authors: Y.-J. Kuo, T.W.-W. Chen, H.-W. Chen, C.-Y. Hsu, W.-H. Lin, P.-M. Huang, J.-C. Lee, H.-M. Chen, K.-H. Huang, C.Y. Yang, C.-C. Chang, R.-S. Yang, R.-L. Hong
Journal: Annals of Oncology (2019)
Assessment of Barriers and Facilitators to the Delivery of Care for Noncommunicable Diseases by Nonphysician Health Workers in Low- and Middle-Income Countries
Authors: David J. Heller, Anirudh Kumar, Sandeep P. Kishore, Carol R. Horowitz, Rohina Joshi, Rajesh Vedanthan
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Cardiovascular disease, cancer, and other noncommunicable diseases (NCDs) are the leading causes of mortality in low- and middle-income countries. Previous studies show that nonphysician health workers (NPHWs), including nurses and volunteers, can provide effective diagnosis and treatment of NCDs. However, the factors that facilitate and impair these programs are incompletely understood. <h3>Objective</h3> To identify health system barriers to and facilitators of NPHW-led care for NCDs in low- and middle-income countries. <h3>Data Sources</h3> All systematic reviews in PubMed published by May 1, 2018. <h3>Study Selection</h3> The search terms used for this analysis included "task shifting" and "non-physician clinician." Only reviews of NPHW care that occurred entirely or mostly in low- and middle-income countries and focused entirely or mostly on NCDs were included. All studies cited within each systematic review that cited health system barriers to and facilitators of NPHW care were reviewed. <h3>Data Extraction and Synthesis</h3> Assessment of study eligibility was performed by 1 reviewer and rechecked by another. The 2 reviewers extracted all data. Reviews were performed from November 2017 to July 2018. All analyses were descriptive. <h3>Main Outcomes and Measures</h3> All barriers and facilitators mentioned in all studies were tallied and sorted according to the World Health Organization's 6 building blocks for health systems. <h3>Results</h3> This systematic review and qualitative analysis identified 15 review articles, which cited 156 studies, of which 71 referenced barriers to and facilitators of care. The results suggest 6 key lessons: (1) select qualified NPHWs embedded within the community they serve; (2) provide detailed, ongoing training and supervision; (3) authorize NPHWs to prescribe medication and render autonomous care; (4) equip NPHWs with reliable systems to track patient data; (5) furnish NPHWs consistently with medications and supplies; and (6) compensate NPHWs adequately commensurate with their roles. <h3>Conclusions and Relevance</h3> Although the health system barriers to NPHW screening, treatment, and control of NCDs and their risk factors are numerous and complex, a diverse set of care models has demonstrated strategies to address nearly all of these challenges. These facilitating approaches—which relate chiefly to strong, consistent NPHW training, guidance, and logistical support—generate a blueprint for the creation and scale-up of such programs adaptable across multiple chronic diseases, including in high-income countries.
Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Authors: Nilofer S. Azad, Robert J. Gray, Michael J. Overman, Jonathan D. Schoenfeld, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Howard Streicher, Shuli Li, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Brent Coffey, Stanley R. Hamilton, Nathan Bahary, J. Marie Suga, Hassan Hatoum, Jeffrey S. Abrams, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Journal of Clinical Oncology (2019)

PURPOSE The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, the largest national precision oncology study to date (&gt; 1,100 sites) of patients with relapsed or refractory malignancies, assigned patients to targeted therapy in parallel phase II studies based on tumor molecular alterations. The anti–programmed death receptor 1 inhibitor nivolumab previously showed activity in mismatch repair (MMR)–deficient colon cancer. We hypothesized that nivolumab would have activity in patients with MMR-deficient, noncolorectal tumors. PATIENTS AND METHODS Eligible patients with relapsed or refractory tumors, good end-organ function, and Eastern Cooperative Oncology Group performance status of ≤ 1 underwent tumor biopsy for centralized screening of molecular alterations. MMR deficiency was defined by complete loss of nuclear expression of MLH1 or MSH2 MMR gene products by immunohistochemistry (IHC). Patients with MMR-deficient colorectal cancer were excluded. Nivolumab, 3 mg/kg every 2 weeks (28-day cycles) and 480 mg every 4 weeks after cycle 4, was administered intravenously. Disease reassessment was performed every 2 cycles. The primary end point was RECIST 1.1 objective response rate (ORR). RESULTS Two percent of 4,902 screened patients had an MMR-deficient cancer by IHC. Forty-two evaluable patients were enrolled, with a median age of 60 years and a median of 3 prior therapies. The most common histologies were endometrioid endometrial adenocarcinoma (n = 13), prostate adenocarcinoma (n = 5), and uterine carcinosarcoma (n = 4). ORR was 36% (15 of 42 patients). An additional 21% of patients had stable disease. The estimated 6-, 12-, and 18-month progression-free survival rates were 51.3% (90% CI, 38.2% to 64.5%), 46.2% (90% CI, 33.1% to 59.3%), and 31.4% (90% CI, 18.7% to 44.2%), respectively. Median overall survival was 17.3 months. Toxicity was predominantly low grade. CONCLUSION A variety of refractory cancers (2.0% of those screened) had MMR deficiency as defined in NCI-MATCH. Nivolumab has promising activity in MMR-deficient noncolorectal cancers of a wide variety of histopathologic types.
Effects of Tai Chi and Qi Gong group class participation on self-reported symptoms in cancer patients and caregivers: A preliminary report.
Authors: Gabriel Lopez, Santhosshi Narayanan, Amie J Christie, Catherine Powers-James, M. Kay Garcia, Wenli Liu, Telma I Gomez, Jimin Wu, Janet L. Williams, Yisheng Li, Eduardo Bruera, Lorenzo Cohen
Journal: Journal of Clinical Oncology (2019)

100 Background: Tai chi and qi gong are movement-based, mind-body approaches offered as part of an integrative oncology program at a comprehensive cancer center. We explored the effects of tai chi and qi gong group class participation on cancer patient and caregiver self-reported symptoms. Methods: Patients and caregivers attending a tai chi and/or qi gong group class completed the Edmonton Symptom Assessment Scale (ESAS) immediately before and after participation. The ESAS assessed 10 symptoms (scale 0-10, 10 worst possible); ESAS subscales analyzed included global (GDS), physical (PHS), and psychosocial (PSS). Descriptive statistics; Chi-Squared test, Fisher’s exact test, Wilcoxon rank-sum test and Wilcoxon signed-rank test were used for data analysis. Results: 304 participants (Oct 2017-April 2019; 184 patients, 120 caregivers; 72% women, 60% white; mean age 58) were included in the analysis. For patients (symptom reduction by class type: tai chi -4.5 SD 7.6; qi gong -6.1 SD 7.9) and caregivers (tai chi -3.7 SD 6.3; qi gong -4.0 SD 7.8), both class types contributed to clinically and statistically significant improvement (ESAS GDS decrease ≥3; p’s ≤0.0001) in global distress. Patients (-2.07 SD 5.49) and caregivers (-2.34 SD 3.71) participating in tai chi experienced clinically and statistically significant improvement in physical distress (ESAS PHS decrease ≥2; p’s ≤0.0001). For the individual symptom of well-being, we observed clinically and statistically significant improvement for caregivers participating in qi gong (-1.2 SD 2) and patients participating in tai chi (-1.0 SD 1.8) (p’s ≤0.0001). For fatigue, patients (-1.4) and caregivers (-1.0) participating in qi gong experienced clinically and statistically significant improvement (p’s ≤0.0001). Conclusions: Patients and caregivers participating in both class types experienced significant improvement in physical and global distress. Additional research is warranted to learn more about how differences in class content (tai chi vs qi gong) and participants may contribute to observed differences in symptom change.
Silent Myocardial Infarction and Sudden Cardiac Death—Finding the Culprit—Reply
Authors: M. Juhani Junttila, Juha H. Vähätalo, Heikki V. Huikuri
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Authors: A. Hata, M. Satouchi, S. Morita, Y. Ota, Y. Urata, Y. Kawa, H. Okada, H. Mayahara, M. Kokubo, Y. Akazawa, T. Uenami, M. Tamiya, K. Kunimasa, K. Nakata, D. Harada, A. Nakamura, N. Takase, N. Katakami, S. Negoro
Journal: Annals of Oncology (2019)
Imatinib induced toxicity and its influence on cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia
Authors: H. Natarajan, L. Kumar, S. Bakhshi, A. Sharma, T. Velpandian, M. Kabra, A. Gogia, N.R. Biswas, Y.K. Gupta
Journal: Annals of Oncology (2019)
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction
Authors: David A. Wood, John A. Cairns, Jia Wang, Roxana Mehran, Robert F. Storey, Helen Nguyen, Brandi Meeks, Vijay Kunadian, Jean-Francois Tanguay, Hahn-Ho Kim, Asim Cheema, Payam Dehghani, Madhu K. Natarajan, Sanjit S. Jolly, John Amerena, Matyas Keltai, Stefan James, Ota Hlinomaz, Kari Niemela, Khalid AlHabib, Basil S. Lewis, Michel Nguyen, Jaydeep Sarma, Vladimir Dzavik, Anthony Della Siega, Shamir R. Mehta
Journal: Journal of the American College of Cardiology (2019)
Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Authors: D.S. Tan, J.J. Chan, J.K. Loke, R. Hettle, W. Ghosh, A. Viswambaram, C.C. Yu
Journal: Annals of Oncology (2019)
Coauthor Country Affiliations in International Collaborative Research Funded by the US National Institutes of Health, 2009 to 2017
Authors: Joshua C. Grubbs, Roger I. Glass, Peter H. Kilmarx
Journal: JAMA Network Open (2019)

The US National Institutes of Health (NIH) is the largest funder of biomedical and behavioral research in the world. International collaborative research-a subset of NIH's portfolio-is critical to furthering the agency's health research mission.To quantify the extent of the NIH's international collaborations and the relative importance of this research through the lens of publications.This cross-sectional study used bibliometric data from the Web of Science database to analyze trends in the growth of NIH-funded publications from January 1, 2009, to December 31, 2017, and examined their importance using national affiliations of all coauthors listed, h indices, and citation impact scores. All countries with coauthor affiliations in NIH-funded publications during the study period were included. Data were analyzed from October 22 through November 16, 2018.Country affiliations of coauthors' institutions in NIH-funded publications indexed in the Web of Science database from 2009 to 2017.Trends in the number of NIH-supported publications with non-US coauthors during a 9-year period and their relative importance assessed by h index per country and category-normalized citation impact (CNCI) for groups of country affiliations in 2017.From 2009 to 2017, the annual count of NIH-funded publications increased 46.2% from 67 041 to 98 002. This increase was driven in part by an increase in publications with a non-US author alone or as a collaborator with a US author compared with those exclusively with US authors, reflected by an increase in the percentage of publications with non-US coauthors from 28.3% to 34.8%. Moreover, in 2017, publications coauthored by US-affiliated and non-US-affiliated investigators had a higher mean CNCI (1.99) than those whose authors were only US affiliated (1.54) or non-US affiliated (1.35). China became the most frequent publishing partner, with 6982 coauthored publications and the greatest increase over time among non-US countries.In a 9-year period when the NIH budget remained relatively unchanged, an increase in the number of publications occurred with a growing trend toward more international collaborations of authorship; these publications also had a higher CNCI than publications with only US or only non-US authors. The findings suggest that international collaboration is a vital and growing component of the NIH's research output and likely reflects increased globalization of biomedical research.
Quality improvement projects are transformative: improving supervision must not dampen enthusiasm
Authors: Timothy P Newson
Journal: BMJ (2019)

Quality improvement (QI) is not the preserve of a trained elite, it should be in the DNA of all healthcare systems and staff.1 In our trust, quality improvement projects have roused enthusiasm for improving patient care and experience—something the long era of focus on clinical audits never achieved.

Since 2017 we’ve had 12 undergraduate QI projects a year supervised by …
The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know
Authors: Andrew D. Zelenetz
Journal: Journal of the National Comprehensive Cancer Network (2019)

Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim-sndz, bevacizumab-awwb, trastuzumab-dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β
Authors: Juan Li, Marco Ritelli, Cindy S. Ma, Geetha Rao, Tanwir Habib, Emilie Corvilain, Salim Bougarn, Sophie Cypowyj, Lucie Grodecká, Romain Lévy, Vivien Béziat, Lei Shang, Kathryn Payne, Danielle T. Avery, Mélanie Migaud, Soraya Boucherit, Sabri Boughorbel, Andrea Guennoun, Maya Chrabieh, Franck Rapaport, Benedetta Bigio, Yuval Itan, Bertrand Boisson, Claire Fieschi, Valérie Cormier-Daire, Delfien Syx, Fransiska Malfait, Nicoletta Zoppi, Laurent Abel, Tomáš Freiberger, Harry C. Dietz, Nico Marr, Stuart G. Tangye, Marina Colombi, Jean-Laurent Casanova, Anne Puel
Journal: Science Immunology (2019)

Human JNK1 is essential for IL-17A/F–dependent mucocutaneous immunity to Candida and for TGF-β–dependent homeostasis of connective tissues.
Sexism at the BMA: grassroots GPs call for “action not words” by next May
Authors: Gareth Iacobucci
Journal: BMJ (2019)

Local GP leaders have demanded that the BMA’s General Practitioners Committee publish a formal action plan for tackling sexism and harassment in the organisation by May next year in response to the damning report into the discriminatory culture at the association.

The independent review by Daphne Romney QC, published last month, reported a culture in which female doctors and staff at the BMA had been bullied, undermined, and in some cases sexually harassed.1 It also criticised the association’s leadership for failing to challenge bad behaviour. The BMA’s governing council met on 13 …